Pigment epithelium-derived factor (PEDF) attenuated capsaicin-induced neurotrophic keratouveitis

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 11, 2009, Pages 5173-5180

  Feher, Janos ^a   Kovacs, Illes ^b   Pacella, Elena ^a   Keresz, Sandor ^c   Spagnardi, Natascia ^c   Gabrieli, Corrado Balacco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c Nutripharma Hungaria Ltd   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSAICIN; PIGMENT EPITHELIUM DERIVED FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL COUNT; CELL INFILTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ELECTRON MICROSCOPY; EYE PROTECTION; FEMALE; HISTOPATHOLOGY; LACRIMAL FLUID; LEUKOCYTE; MALE; NEOVASCULARIZATION (PATHOLOGY); NEUROTROPHIC KERATOUVEITIS; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RAT; SCAR FORMATION; SCHIRMER TEST; SLIT LAMP; UVEITIS; VITREOUS BODY;

ANIMALS; CAPSAICIN; CORNEA; CRANIAL NERVE DISEASES; EYE PROTEINS; FEMALE; INJECTIONS; MALE; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; NERVE GROWTH FACTORS; OPHTHALMIC NERVE; ORBIT; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; SENSORY SYSTEM AGENTS; SERPINS; TEARS; UVEITIS, ANTERIOR;

EID: 78649410157     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-1852     Document Type: Article

References (53)

1. Beuerman RW, Stern ME. Neurogenic inflammation: a first line of defense for the ocular surface. Ocul Surf. 2005;3(suppl): S203-6.
2. Troger J, Kieselbach G, Teuchner B, et al. Peptidergic nerves in the eye, their source and potential pathophysiological relevance. Brain Res Res. 2007;53:39-62.
3. Stern ME, Gao J, Siemasko KF, et al. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res. 2004;78:409-416.
4. Kovács I, Ludány A, Koszegi T, et al. Substance P released from sensory nerve endings influences tear secretion and goblet cell function in the rat. Neuropeptides. 2005;39:395-402.
5. Feher J. Contribution of neurogenic inflammation to irritable eye syndrome. Adv Exp Med Biol. 2002;506:1047-1050.
6. Baudouin C. A new approach for better comprehension of diseases of the ocular surface. J Fr Ophtalmol. 2007;30:239-246.
7. Tuisku IS, Lindbohm N, Wilson SE, et al. Dry eye and corneal sensitivity after high myopic LASIK. J Refract Surg. 2007;23:338-342.
8. Mishima S. The effects of the denervation and the stimulation of the sympathetic and the trigeminal nerve on the mitotic rate of the corneal epithelium in the rabbit. Jpn J Ophthalmol. 1957; 1:65-73.
9. Baker KS, Anderson SC, Romanowski EG, et al. Trigeminal ganglion neurons affect corneal epithelial phenotype: influence on type VII collagen expression in vitro. Invest Ophthalmol Vis Sci. 1993;34:137-144.
10. Davis EA, Dohlman CH. Neurotrophic keratitis. Int Ophthalmol Clin. 2001;41:1-11.
11. Araki K, Ohashi Y, Kinoshita S, et al. Epithelial wound healing in the denervated cornea. Curr Eye Res. 1994;13:203-211.
12. Zaal MJ, Völker-Dieben HJ, D'Amaro J. Risk and prognostic factors of postherpetic neuralgia and focal sensory denervation: a prospective evaluation in acute herpes zoster ophthalmicus. Clin J Pain. 2000;16:345-351.
13. Didenko TN, Smoliakova GP, Sorokin EL, et al. Clinical and pathogenetic features of neurotrophic corneal disorders in diabetes (in Russian). Vestn Oftalmol. 1999;115:7-11.
14. Pushker N, Dada T, Vajpayee RB, et al. Neurotrophic keratopathy. CLAO J. 2001;27:100-107.
15. Smith SA, Smith SE. Evidence for a neuropathic aetiology in the small pupil of diabetes mellitus. Br J Ophthalmol. 1983;67:89-93.
16. Stjernschantz J. Studies on ocular inflammation and development of a prostaglandin analogue for glaucoma treatment. Exp Eye Res. 2004;78:759-766.
17. Brecha NC, Sternini C, Anderson K, et al. Expression and cellular localization of substance P/neurokinin A and neurokinin B mRNAs in the rat retina. Visual Neurosci. 1989;3:527-535.
18. Caruso DM, Owczarzak MT, Pourcho RG. Colocalization of substance P and GABA in retinal ganglion cells: a computer-assisted visualization. Vis Neurosci. 1990;5:389-394.
19. Bagnoli P, Dal Monte M, Casini G. Expression of neuropeptides and their receptors in the developing retina of mammals. Histol Histopathol. 2003;18:1219-1242.
20. May A, Shepheard SL, Knorr M, et al. C. Retinal plasma extravasation in animals but not in humans: implications for the pathophysiology of migraine. Brain. 1998;121:1231-1237.
21. Gaspar MN, Ribeiro CA, Cunha-Vaz JG, et al. Effects of neuropeptides on the sumatriptan-disturbed circulation in the optic nerve head of rabbits. Pharmacology. 2004;70:152-159.
22. Nucci C, Gasperi V, Tartaglione R, et al. Involvement of the endocannabinoid system in retinal damage after high intraocular pressure-induced ischemia in rats. Invest Ophthalmol Vis Sci. 2007;48:2997-3004.
23. Bronzetti E, Artico M, Kovacs I, et al. Expression of neurotransmitters and neurotrophins in neurogenic inflammation of the rat retina. Eur J Histochem. 2007;51:251-260.
24. Szolcsanyi J. Forty years in capsaicin research for sensory pharmacology and physiology. Neuropeptide. 2004;38:377-384.
25. Fujita S, Shimizu T, Izumi K, et al. Capsaicin-induced neuroparalytic keratitis-like corneal changes in the mouse. Exp Eye Res. 1984;38:165-175.
26. Ogilvy CS, Silverberg KR, Borges LF. Sprouting of corneal sensory fibers in rats treated at birth with capsaicin. Invest Ophthalmol Vis Sci. 1991;32:112-121.
27. Gallar J, Pozo MA, Rebollo I, et al. Effects of capsaicin on corneal wound healing. Invest Ophthalmol Vis Sci. 1990;31:1968-1974.
28. Waldrep JC, Crosson CE. Induction of keratouveitis by capsaicin. Curr Eye Res. 1988;7:1173-1182.
29. Ritter S, Dinh TT. Capsaicin-induced neuronal degeneration in the brain and retina of preweanling rats. J Comp Neurol. 1990;296: 447-461.
30. Tombran-Tink J, Shivaram SM, Chader GJ, et al. Expression, secretion, and age-related downregulation of pigment epithelium-derived factor, a serpin with neurotrophic activity. J Neurosci. 1995; 15:4992-5003.
31. Becerra SP, Palmer I, Kumar A, et al. Overexpression of fetal human pigment epithelium-derived factor in Escherichia coli: a functionally active neurotrophic factor. J Biol Chem. 1993;268: 23148-23156.
32. Dawson DW, Volpert OV, Gillis P, et al. Pigment epitheliumderived factor: a potent inhibitor of angiogenesis. Science. 1999; 285:245-258.
33. Chung C, Doll JA, Stellmach VM, et al. Pigment epithelium-derived factor is an angiogenesis and lipid regulator that activates peroxisome proliferator-activated receptor alpha. Adv Exp Med Biol. 2008;617:591-597.
34. Bouck N. PEDF: anti-angiogenic guardian of ocular function. Trends Mol Med. 2002;8:330-334.
35. Spranger J, Osterhoff M, Reimann M, et al. Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes. 2001;50:2641-2645.
36. Nakamura M, Kawahara M, Nakata K, et al. Restoration of corneal epithelial barrier function and wound healing by substance P and IGF-1 in rats with capsaicin-induced neurotrophic keratopathy. Invest Ophthalmol Vis Sci. 2003;44:2937-2940.
37. Szallasi A, Blumberg PM. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev. 1999;51:159-212.
38. Gunthorpe MJ, Szallasi A. Peripheral TRPV1 receptors as targets for drug development: new molecules and mechanisms. Curr Pharm Des. 2008;14:32-41.
39. Zhang F, Yang H, Wang Z, et al. Transient receptor potential vanilloid 1 activation induces inflammatory cytokine release in corneal epithelium through MAPK signaling. J Cell Physiol. 2007; 213:730-739.
40. Zimov S, Yazulla S. Vanilloid receptor 1 (TRPV1/VR1) co-localizes with fatty acid amide hydrolase (FAAH) in retinal amacrine cells. Vis Neurosci. 2007;24:581-591.
41. Sappington RM, Calkins DJ. Contribution of TRPV1 to microgliaderived IL-6 and NFkappaB translocation with elevated hydrostatic pressure. Invest Ophthalmol Vis Sci. 2008;49:3004-3017.
42. Lázár J, Szabó T, Marincssák R, et al. Sensitization of recombinant vanilloid receptor-1 by various neurotrophic factors. Life Sci. 2004; 75:153-163.
43. Amaya F, Shimosato G, Nagano M, et al. NGF and GDNF differentially regulate TRPV1 expression that contributes to development of inflammatory thermal hyperalgesia. Eur J Neurosci. 2004;20: 2303-2310.
44. Zhang X, Huang J, McNaughton PA. NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J. 2005;24:4211-4223.
45. Anand U, Otto WR, Casula MA, et al. The effect of neurotrophic factors on morphology, TRPV1 expression and capsaicin responses of cultured human DRG sensory neurons. Neurosci Lett. 2006;399:51-56.
46. Evans RM, Scott RH, Ross RA. Chronic exposure of sensory neurones to increased levels of nerve growth factor modulates CB1/TRPV1 receptor crosstalk. Br J Pharmacol. 2007;152:404-413.
47. Aloe L, Tirassa P, Lambiase A. The topical application of nerve growth factor as a pharmacological tool for human corneal and skin ulcers. Pharmacol Res. 2008;57(4):253-258.
48. Lambiase A, Rama P, Bonini S, et al. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med. 1998;338:1174-1180.
49. Barnstable CJ, Tombran-Tink J. Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential. Prog Retin Eye Res. 2004;23:561-577.
50. Gao G, Li Y, Zhang D, et al. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett. 2001;489:270-276.
51. Jin KL, Mao XO, Greenberg DA. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci U S A. 2000;97:10242-10247.
52. Zachary I. Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. Neurosignals. 2005;14:207-221.
53. Khaibullina AA, Rosenstein JM, Krum JM. Vascular endothelial growth factor promotes neurite maturation in primary CNS neuronal cultures. Brain Res Dev Brain Res. 2004;148:59-68.